Updated: Jun 12, 2020
There's a buzz going round about an enzyme called EZH2 and an exciting new study which has identified it as the missing public enemy no.1 in Postural Orthostatic Tachycardia Syndrome. There have also been big claims that a new drug GSK-126 will tackle EZH2 and be a major breakthrough for POTS sufferers. Want to know more?
A research team at Monash uni in Austrailia recently discovered that in people with POTS the normally beneficial enzyme EZH2 (aka 'enhancer of zeste homolog 2') fails to work properly causing it to silence or 'switch off' the much needed norepinephrine gene.
What does this norepinephrine gene do? Well, a whole lot of stuff to do with mood control, anxiety and the stress response, and your ability to concentrate. However, the part we're interested in here is the protein called NET (norepinephrine transporte